Stock Analysis of Editas Medicine Inc (EDIT) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code EDIT
Close 5.20
Change 0.0300 / 0.580 %
Volume 2428.93 K
Vol Change 683793 / 39.18 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Editas Medicine Inc
PE (TTM)

-1198.71

Very Poor
Price / Book

552.63

Very Poor
Price / Sales

2869.24

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

427637 K

Enterprise Value

316149 K

ROA (TTM)

-33.90

Very Poor
ROE (TTM)

-48.26

Very Poor
Net Margin (TTM)

-239.36

Very Poor
Revenue

24.85 %

24610.00 K
Net Profit

11.50 %

-195083.00 K
Debt to Equity

0.0348

Excellent
Altman Z Score

-2.32

Very Poor
Quick Ratio

0

Poor
Cash Ratio

5.11

Very Good


Highs/Lows of Editas Medicine Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.63 7.64 % 0.513 % 5.84.990128-May-2429-May-24
Two Week5.62 7.47 % 0.486 % 6.184.990122-May-2429-May-24
One Month5.21 0.192 % 4.80 % 6.694.9115-May-2408-May-24
Three Month10.06 48.31 % 3.56 % 11.0554.9101-Mar-2408-May-24
Six Months10.53 50.62 % 15.54 % 11.694.9106-Dec-2308-May-24
One year9.18 43.36 % 26.26 % 11.94.9114-Jun-2308-May-24
Two year11.39 54.35 % 27.72 % 14.234.9102-Nov-2208-May-24
Five year20.55 74.70 % 91.77 % 16.614.9125-Aug-2208-May-24


Technical View of Editas Medicine Inc
RSI

40.88

Neutral
MACD

-0.194

Strong Bearish
ADX

14.08

Neutral
Super Trend

6.21

Mild Bearish
Williams %R

-87.65

Mild Bullish
CCI

-99.68

Strong Bullish


EMA 5

5.29

Mild Bearish
EMA 15

5.49

Strong Bearish
EMA 50

6.11

Strong Bearish
EMA 100

6.88

Strong Bearish
SMA 100

7.15

Mild Bearish
SMA 200

7.93

Strong Bearish
SMA 5 / 20

5.28 / 5.56

Bearish
SMA 15 / 50

5.57 / 6.02

Mild Bearish
SMA 50 / 200

6.02 / 7.93

Strong Bearish




Charts of Editas Medicine Inc


Returns of Editas Medicine Inc with Peers
Period / StockEDITTALKVERVBVS
1 Week-7.64%-8.39%-1.70%5.02%
1 Mth-0.192%-14.38%-13.64%68.94%
3 Mth-48.31%-10.88%-69.56%44.49%
6mth-50.62%28.43%-53.99%67.25%
1 Year-43.36%144.86%-66.47%147.32%
2 Year-54.35%85.82%-65.77%-32.29%
5 Years-74.70%---
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Editas Medicine Inc with Peers
Ratio / StockEDITTALKVERVBVS
PE-1198.71-60.87-1.71-19.46
P/B552.633.650.6431.85
ROA-33.90-5.07-29.63-2.61
ROE-48.26-6.00-37.60-12.11
Debt To Equity0.034800.01702.27
Revenue24610.00 K
24.85 % 		137868 K
15.31 % 		7626.00 K
292.89 % 		502756 K
1.83 %
Net Income-195083.00 K
11.50 % 		-36183.00 K
54.59 % 		-192801.00 K
22.50 % 		-182064.00 K
14.72 %


Technicals of Editas Medicine Inc with Peers
Technical / StockEDITTALKVERVBVS-
ADX14.0811.9726.1537.06
CMF-0.306-0.280-0.3270.269
MFI48.9439.7939.2870.89
RSI40.8835.1727.8869.18
MACD Abv SignalFalseFalseTrueTrue
Price Above 50 MAFalseFalseFalseTrue-
Price Above 200 MAFalseTrueFalseTrue-


About : Editas Medicine Inc

Address : 11 Hurley Street, Cambridge, MA, United States, 02141
Tel : 617 401 9000
URL : https://www.editasmedicine.com
Code : EDIT, ISIN : US28106W1036, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 03_Feb_2016
Employee Count : 265

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)